Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8 (Search time: 0.003 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2004Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexilineDavies, B.; Coller, J.; James, H.; Gillis, D.; Somogyi, A.; Horowitz, J.; Morris, R.; Sallustio, B.
2012Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patientsColler, J.; Michalakas, J.; James, H.; Farquharson, A.; Colvill, J.; White, J.; Somogyi, A.
2005The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemiaDavies, B.; Coller, J.; James, H.; Somogyi, A.; Horowitz, J.; Sallustio, B.
2004A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysisJames, H.; Coller, J.; Gillis, D.; Bahnisch, J.; Sallustio, B.; Somogyi, A.
2007Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemiaInglis, S.; Herbert, M.; Davies, B.; Coller, J.; James, H.; Horowitz, J.; Morris, R.; Milne, R.; Somogyi, A.; Sallustio, B.
2003Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.Sallustio, B.; Davies, B.; Coller, J.; James, H.; Gillis, D.; Somogyi, A.
2012Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjectsGelston, E.; Coller, J.; Lopatko, O.; James, H.; Schmidt, H.; White, J.; Somogyi, A.
2007Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadonColler, J.; Joergensen, C.; Foster, D.; James, H.; Gillis, D.; Christrup, L.; Somogyi, A.